Current state of clinical trials in breast cancer brain metastases

Abstract

Background Breast cancer brain metastases (BCBM) are the final frontier in neuro-oncology for which more efficacious therapies are required. In this work, we explore clinical trials in BCBM, and determine the shortcomings in the development of new BCBM therapies to shed light on potential areas for enhancement. Methods On July 9, 2018, we searched ClinicalTrials.gov for all interventional and therapeutic clinical trials involving BCBM, without limiting for date or location. Information on trial characteristics, including phase, status, start and end dates, study design, primary endpoints, selection criteria, sample size, experimental interventions, results, and publications were collected and analyzed. Results Fifty-three trials fulfilled the selection criteria. Median trial duration across phases ranged between 3 and 6 years. More than half of the trials were conducted in the United States. Although 94% of the trials were in early phases (I-II), 20% of patients were in phase III trials. Two phase III trials were anteceded by phase II trials that were non-randomized; one reported positive results. Approximately one-third of the trials were completed, whereas 23% of trials were terminated early; mostly due to inadequate enrollment. Only 13% of all trials and 22% of completed trials had published results directly linked to their primary outcomes. Conclusions The low number of trials and accrual numbers, the lack of diversity, and the scarcity of published results represent the main troubles in clinical BCBM research. Optimization of BCBM trials is necessary to achieve effective therapies.

Molecular principles of metastasis: a hallmark of cancer revisited

“…In addition, the exclusion of patients with metastasis from clinical trials prevented faster progress. 223 However, advancements in the field have changed the reigning paradigm and offered hope for future success. A photoacoustic method for direct use in patients with melanoma has been developed, allowing for the detection of very low numbers of CTCs in vivo and their subsequent destruction with laser pulses.…”

“…Major obstacles lie in the lack of clinical trials that target metastasis and the lack of knowledge of the biological underpinnings that govern the metastatic process. 169,171,220,223 Designing targeted therapies for metastatic cancer cells should take into account the genetic and phenotypic differences between parental and metastatic/circulating cells. 294 Today, the diagnosis of metastatic cancer continues to be associated with a terminal label.…”

“…302 Therefore, agents that are known to cross the BBB must be tested in brain metastasis settings and novel agents with the ability to cross the BBB must be designed. 223 Overall, metastasis is a complex challenge that requires more than one therapeutic agent for effective inhibition. Therefore, embracing the combination therapy model and targeting multiple pathways simultaneously seems to be key to countering the significant genomic and phenotypic alterations presented by metastatic cancer cells.…”

Health communication research in the Arab world: A bibliometric analysisHealth communication research in the Arab world: A bibliometric analysis

“…In Lebanon, health communication studies mostly focused on three major health problems that the nationals in the country deal with: cancer, smoking and the refugee crisis. Promoting cancer awareness and establishing treatment guidelines were the focus of two health communication papers,10 11 especially after the rise in the number of cancer cases in the past decade 12–15. Another study explored the role of religion in dictating smoking behaviour in the country 16.…”

Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis

“…Nonetheless, overall research regarding the treatment of BCBM patients have not been rigorous. Fares et al identified several factors impeding the BCBM research such as low number of trials, low accrual numbers, and lack of diversity (96). In addition, these hurdles would also need to be overcome through proper selection of treatment regimens to be investigated.…”